Over the last decade alone, the U.S. healthcare system has saved $1.67 trillion due to the availability of low-cost generics, according to the 2017 Generic Drug Access and Savings Report. Even greater cost savings can be achieved if a more efficient generic drug review process is in place feels the FDA Commissioner Scott Gottlieb, and the regulatory agency is taking steps to achieve this goal.
from RTT - Biotech http://ift.tt/2Bk4mZk
via IFTTT
No comments:
Post a Comment